Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
Summary
MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive.
Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.
Study Design
Time Perspective: Prospective
Conditions
Follicular Lymphoma
Location
Dept. of Nuclear Medicine, Saarland University Hospital
Homburg (Saar)
Saarland
Germany
66421
Status
Recruiting
Source
University Hospital, Saarland
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01151358
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:12:37-0400
Clinical Trials
A Study of Enzastaurin in Patients With Follicular Lymphoma
To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in patients with Follicular Lymphoma.
A Study for Patients With Non-Hodgkin's Lymphomas
In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and A...
Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma
This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL) and evaluate the ...
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Ritux an (rituximab) in previously untreated patients with follicular lymphoma. Data w ill be collected for 3 yea...
An Italian Experience on Grade 3b Follicular Lymphoma
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histolo...
PubMed Articles
The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma.
Patients with low tumor burden follicular lymphoma (FL) are commonly managed with watchful waiting (WW). The incidence of organ dysfunction and/or transformation at disease progression, and subsequent...
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immun...
Diagnosis and treatment of follicular lymphoma: an update.
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to...
Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era.
Intramuscular Follicular Lymphoma.
We present an interesting image of a painless growing mass of the right arm in a 76-year-old man. A musculoskeletal MRI of the right arm showed a 7.5 × 3-cm homogeneous, well-defined mass, elongated ...
Medical and Biotech [MESH] Definitions
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Genes, Bcl-2
The B-cell leukemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
Follicular Phase
The period of the MENSTRUAL CYCLE representing follicular growth, increase in ovarian estrogen (ESTROGENS) production, and epithelial proliferation of the ENDOMETRIUM. Follicular phase begins with the onset of MENSTRUATION and ends with OVULATION.
Precursor T-cell Lymphoblastic Leukemia-lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
Lymphoma, Aids-related
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
